Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Compugen; Sirius Genomics; Olink Genomics; PerkinElmer; GATC Biotech

NEW YORK (GenomeWeb News) – Compugen this week said that it has inked a deal to license to an unnamed diagnostic firm the biomarker candidate CGEN-226 for early detection of preeclampsia. Compugen used its in silico platform to identify the marker, which is a soluble splice variant of the vascular endothelial growth factor. (This brief has been corrected to state that Compugen licensed the biomarker to the unnamed partner rather than from the partner.)


Sirius Genomics has signed an agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), under which the program will provide funding for studying genomic correlations in severe sepsis patients. Sirius will use the funds to continue developing its pharmacogenomic assay to assess responsiveness to recombinant human activated Protein C, which is developed and marketed by Eli Lilly under the tradename Xigris, in patients with severe sepsis at high risk of death.


Researchers at the Karolinska Institutet will use Olink Genomics' Selector Technology for next-generation sequencing studies, as part of an early access program for the reagent kits.


PerkinElmer received clearance from the US Food and Drug Administration this week for its GSP Genetic Screening processor, which can run more than one test on very small samples from newborns. The automated platform can quantitatively and qualitatively analyze blood spot samples for irregularities associated with metabolic diseases.


GATC Biotech will open a sequencing laboratory in London to provide scientists in the UK and Ireland with single sample sequencing services. The lab will start operations in early January, GATC said this week.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more